Program
ibrutinib
Also written as “Ibrutinib”, “PCI-32765” and “PCI-32765 (Ibrutinib)”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Waldenstrom Macroglobulinemia · Lymphoma, Large B-Cell, Diffuse · Multiple Myeloma, led by 5 companies.
Drug pageIbrutinib: every studyMany companies study it; this page follows only the 74 they lead. All 264 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 364 open or running | phase 4since Jun 14, 2017 | May 14, 2012 | Dec 31, 2026phase 3 · NCT01804686 |
| AbbVieits history only | 341 open or running | phase 4since Jun 5, 2017 | Feb 20, 2009 | May 10, 2027phase 4 · NCT03229200 |
| Novartisits history only | 21 open or running | phase 2since May 21, 2019 | Mar 13, 2019 | Jun 30, 2027phase 2 · NCT03960840 |
| BeOne Medicinesits history only | 10 open or running | phase 3since Feb 7, 2017 | Feb 7, 2017 | none ahead |
| Oncternal Therapeuticsits history only | 10 open or running | phase 3since Jun 9, 2022 | Jun 9, 2022 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since May 14, 2012.
- Mar 2, 20152 phase 1 studiesNCT02381080, NCT02390609
- Jun 30, 2015Phase 1 study in Leukemia, LymphoidNCT02556892 · 8 enrolled · Japan
- Dec 18, 2015Phase 1 study in HealthyNCT02638116 · 20 enrolled · Belgium
- Mar 3, 2016Phase 3 study in Lymphoma, Non-HodgkinNCT02703272 · 72 enrolled · United States, Belgium, Brazil and more
- Jun 15, 2016Phase 1 study in HealthyNCT02841150 · 102 enrolled · United States
- Aug 19, 2016Phase 1 study in HealthyNCT02877225 · 103 enrolled · United States
- Jun 14, 2017Phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03190330 · 75 enrolled · India
- Sep 29, 2017Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03301207 · 25 enrolled · Poland, Spain
- Mar 6, 20182 phase 3 studiesNCT03462719, NCT03474679
- Jul 31, 2019Phase 4 study in Waldenstrom MacroglobulinemiaNCT04042376 · 17 enrolled · China
- Aug 19, 2019Phase 2 study in Waldenstrom MacroglobulinemiaNCT04062448 · 16 enrolled · Japan
- Sep 30, 2022Phase 2 study in Lymphoma, Mantle-CellNCT05564052 · 36 enrolled · Brazil, Czechia, Greece and more
- Jul 19, 2023Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05963074 · 333 enrolled · United States, Canada, Czechia and more
- Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteNCT06788509 · 120 planned · Australia, Belgium, Denmark and more
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT01804686
- Dec 15, 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05963074
- Jan 19, 2028Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06788509
TargetBeta
“An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 36 Johnson & Johnson leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more | 1 | By invitation | Jan 19, 2028 | 120 |
| NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada, Czechia and more | 2 | Active, not recruiting | Dec 15, 2027 | 333 |
| NCT05564052Lymphoma, Mantle-Cell · Brazil, Czechia, Greece and more | 2 | Completed | Dec 6, 2023 | 36 |
| NCT04062448Waldenstrom Macroglobulinemia · Japan | 2 | Completed | Aug 24, 2021 | 16 |
| NCT04042376Waldenstrom Macroglobulinemia · China | 4 | Completed | Mar 19, 2024 | 17 |
| NCT03474679Graft vs Host Disease · Japan | 3 | Completed | Nov 29, 2021 | 19 |
| NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell · United States, Belgium, Canada and more | 3 | Active, not recruiting | Feb 26, 2021 | 211 |
| NCT03301207Leukemia, Lymphocytic, Chronic, B-Cell · Poland, Spain | 1 | Completed | Jul 17, 2018 | 25 |
| NCT03190330Leukemia, Lymphocytic, Chronic, B-Cell · India | 4 | Completed | May 3, 2023 | 75 |
| NCT02877225Healthy · United States | 1 | Completed | Nov 11, 2016 | 103 |
| NCT02841150Healthy · United States | 1 | Completed | Aug 2016 | 102 |
| NCT02703272Lymphoma, Non-Hodgkin · United States, Belgium, Brazil and more | 3 | Terminated | Jun 11, 2021 | 72 |
| NCT02638116Healthy · Belgium | 1 | Completed | Mar 2016 | 20 |
| NCT02556892Leukemia, Lymphoid · Japan | 1 | Completed | Aug 20, 2018 | 8 |
| NCT02390609Healthy · Belgium | 1 | Completed | Nov 2015 | 40 |
| NCT02381080Leukemia, Lymphocytic, Chronic, B-Cell · Canada, Russian Federation, Spain | 1 | Completed | Jun 24, 2016 | 26 |
| NCT02329847Hematologic Neoplasms · United States, Australia, Israel and more | 2 | Completed | Feb 9, 2022 | 144 |
| NCT02271438Healthy · Belgium | 1 | Completed | Apr 2015 | 28 |
| NCT02169180Lymphoma, Mantle-Cell · Japan | 2 | Completed | Nov 2016 | 16 |
| NCT01974440Lymphoma · United States, Argentina, Australia and more | 3 | Completed | May 30, 2022 | 403 |
| NCT01973387Leukemia, Lymphocytic, Chronic, B-Cell · Australia, China, Malaysia and more | 3 | Completed | Dec 1, 2015 | 160 |
| NCT01969266Healthy Volunteer · United States | 1 | Completed | Nov 2013 | 8 |
| NCT01866033Healthy Volunteer · Belgium | 1 | Completed | Aug 2013 | 8 |
| NCT01855750Lymphoma · United States, Argentina, Australia and more | 3 | Completed | Feb 26, 2018 | 838 |
| NCT01820936Healthy Volunteers · United States | 1 | Completed | Jun 2013 | 52 |
| NCT01804686Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | Dec 31, 2026 | 539 |
| NCT01779791Lymphoma · United States, Australia, Belgium and more | 2 | Completed | May 18, 2016 | 110 |
| NCT01776840Lymphoma, Mantle-Cell · United States, Argentina, Australia and more | 3 | Completed | Jun 30, 2021 | 523 |
| NCT01767948Hepatic Impairment · United States | 1 | Completed | Nov 2013 | 30 |
| NCT01763021Healthy Participants · United States | 1 | Completed | Jan 2013 | 18 |
| NCT01704963Neoplasms · Japan | 1 | Completed | Nov 20, 2015 | 15 |
| NCT01674322Healthy Participants · Belgium | 1 | Completed | Sep 2012 | 6 |
| NCT01646021Lymphoma, Mantle-Cell · Belgium, Brazil, Canada and more | 3 | Completed | Jun 5, 2015 | 280 |
| NCT01626651Healthy · United States | 1 | Completed | Aug 2012 | 21 |
| NCT01611090Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Belgium and more | 3 | Completed | Jan 23, 2019 | 578 |
| NCT01599949Lymphoma, Mantle-Cell · United States, Belgium, France and more | 2 | Completed | May 2015 | 120 |
How it is read
Names in the registry
- “Ibrutinib”, 49 entries
- “PCI-32765”, 10 entries
- “ibrutinib”, 6 entries
- “PCI-32765 (Ibrutinib)”, 2 entries
- “SNX-5422 plus ibrutinib”, 2 entries
Codes read as this program: PCI32765.
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 23 studies
- Lymphoma, Mantle-Cell, 8 studies
- Waldenstrom Macroglobulinemia, 5 studies
- Lymphoma, Large B-Cell, Diffuse, 4 studies
- Multiple Myeloma, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.